PISCATAWAY, NJ - Sabinsa Corporation has once again successfully protected its intellectual property (IP). Mark C. Sysler, Sabinsa’s Sr. EVP for Marketing and Sales today announced that the US District Court in New Jersey has entered a default judgment on behalf of Sabinsa against GCI Nutrients of Burlingame, CA.

Sabinsa filed suit against GCI in May of 2002 for infringement of its ForsLean® patent # 5,804,596 entitled "Method of Preparing a Forskohlin Composition from Forskohlin Extract and Use of Forskohlin for Promoting Lean Body Mass and Treating Mood Disorders".

The judgment stipulated that GCI had infringed Sabinsa’s patent by importing, selling or offering for sale Coleus forskohlii extracts and that GCI was permanently enjoined from infringing, or contributing to infringe, or inducing the infringement of Sabinsa’s patent #5,804,596 for the remaining patent term. It further ordered that GCI pay Sabinsa’s legal fees.

Sysler commented that "this result was just and proper and should serve as a warning to anyone contemplating an encroachment upon Sabinsa's intellectual property rights. We are committed to our product development and new product research, and must enforce our IP rights in order to continue that commitment".

Sabinsa Corporation, which has pioneered the introduction of several Ayurvedic herbal extracts in the US market, is an application-oriented manufacturing and marketing company which manufacturers Phytonutrients, Ayurvedic herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical, cosmeceutical and food products. Sabinsa distinguishes itself by its extensive research support for its customers and products, and the scientific credentials of its key technical staff.